GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Price-to-Funds-From-Operations

SELLAS Life Sciences Group (FRA:RXK3) Price-to-Funds-From-Operations : (As of Jun. 19, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.